肾络安方治疗肥胖型早期糖尿病肾病的临床疗效及相关炎症机理探讨

【目的】观察肾络安方对肥胖型早期糖尿病肾病的治疗效果并探讨其可能的机制。【方法】将68例肥胖型早期糖尿病肾病患者随机分为对照组和治疗组,每组各34例。2组均给予调整生活方式、饮食控制、降压、降糖、降脂等基础治疗,对照组同时给予厄贝沙坦口服,治疗组在对照组基础上加用肾络安方治疗。治疗16周后,比较2组治疗前后中医证候积分、体质量指数(BMI)、血液指标血胱抑素C(Cys C)、血β2微球蛋白(β2-MG)、同型半胱氨酸(Hcy)、空腹血糖(FBG)]及尿液指标尿单核细胞趋化蛋白-1/尿肌酐(UMCP-1/UCR)、正常T细胞活化后表达和分泌调节蛋白/尿肌酐(URANTES/UCR)、尿白蛋白—肌酐比值(UACR)、尿白蛋白排泄率(UAER)]的变化情况,并评价其疗效及安全性。【结果】1治疗过程中5例脱落,63例(治疗组32例、对照组31例)完成试验。2治疗组总有效率为90.6%,明显优于对照组的67.7%(P0.05)。3治疗后,2组BMI均较治疗前明显降低(P0.05)。4治疗后,治疗组的各项中医证候积分、血液指标(Cys C、β2-MG、Hcy、FBG)及尿液指标(UMCP-1/UCR、URANTES/UCR、UACR、UAER)均较本组治疗前及对照组治疗后明显降低(P0.05)。5UMCP-1/UCR、URANTES/UCR、UACR、UAER相互呈正相关。6本试验中63例患者治疗前后血常规、大便常规、肝功能、心电图等安全性指标检测均未发现明显异常改变。【结论】肾络安方结合西药治疗肥胖型早期糖尿病肾病具有较好的疗效,可以减轻临床症状,降低BMI、Cys C、β2-MG、UACR、UAER水平,减少UMCP-1、URANTES排泄,其作用机制可能与肾络安方联合西药能抑制肾脏慢性炎症有关。

Therapeutic Effect of Shenluo'an Decoction for Obese Patients with Early Diabetic Nephropathy and Its Anti-inflammation Mechanism

Objective To observe the therapeutic effect of Shenluo'an Decoction(SD) for the treatment of obese patients with early diabetic nephropathy and to explore the possible mechanism.Methods A total of 68 obese patients with early diabetic nephropathy were randomly assigned into control group and treatment group,34 cases in each group.Both groups were given conventional western medicine treatment including lifestyle regulation,dietary control,and medicine for lowering blood pressure,blood glucose and blood lipids.Additionally,the control group was given oral use of Irbesartan,and the treatment group was given oral use of SD combined with Irbesartan.Before and after treatment,we observed the traditional Chinese medical syndrome scores,body mass index(BMI),blood levels of cystatin C (Cys C),β2-microglobumin(β2-MG),homocysteine (Hcy) and fasting blood glucose (FBG),and urine parameters of urinary monocyte chemoattractant protein-1 / urinary creatinine (UMCP-1/UCR),urinary factor of regulated on activation in normal T cell expressed and secreted / urinary creatinine (URANTES/UCR),urinary albumin-to-creatinine ratio (UACR) and urinary albumin excretion ratio (UAER) before treatment and after treatment for 16 weeks.After treatment,the clinical efficacy and safety were also evaluated.Results (1) During the treatment,5 cases were dropped out,and a total of 63 cases (32 from the treatment group and 31 from the control group) completed the experiment.(2) The total effective rate of the treatment group(90.6％) was significantly higher than that of the control group(67.7％),the difference being significant(P ＜ 0.05).(3)BMI of the two groups after treatment was significantly lower than that before treatment (P ＜ 0.05).(4) After treatment,the traditional Chinese medical syndrome scores,blood parameters (Cys C,β2-MG,Hcy,FBG) and urine parameters (UMCP-1/UCR,URANTES/UCR,UACR,UAER) in the treatment group were decreased as compared with those before treatment and those in the control group after treatment(P ＜0.05).(5) A positive correlation was present among the parameters of UMCP-1/UCR,URANTES/UCR,UACR and UAER.(6) No abnormal changes took place in the blood and stool routine examination,hepatic function,or electrocardiography of the 63 cases.Conclusion SD combined with western medicine exerts certain therapeutic effect for obese patients with early diabetic nephropathy,and is effective on relieving clinical symptoms anddecreasing BMI,Cys C,β2-MG,UACR,UAER,UMCP-1 and URANTES.Its mechanism is probably related with the inhibition of chronic renal inflammation.